Researchers in California have revealed how often cancers return and spread in the body among young cancer patients.
First-line use of encorafenib and binimetinib in BRAF V600E NSCLC recorded a median overall survival of 47.6 months, according to data presented at the ESMO congress.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback